Indivior Projects Accelerated Growth, Completes Action Agenda Phase I

Event summary

  • Indivior projects full-year 2026 total net revenue between $1.125 billion and $1.195 billion, with SUBLOCADE revenue expected to be between $905 million and $945 million.
  • The company anticipates non-GAAP operating expenses of $430 million to $450 million and adjusted EBITDA between $535 million and $575 million.
  • Indivior has completed Phase I of its 'Indivior Action Agenda,' which included organizational simplification and operating model transformation, resulting in at least $150 million in annual non-GAAP operating expense savings.
  • Shareholder approval was secured to change the company's domicile from the U.K. to the U.S., with the change expected to be effective January 26, 2026.
  • Indivior concluded a legacy U.S. Department of Justice matter by paying a $295 million obligation.

The big picture

Indivior's guidance signals a renewed focus on growth following a transition year. The company's reliance on SUBLOCADE, which generates the vast majority of revenue, makes it vulnerable to market saturation and competitive pressures. The domicile change aims to improve access to capital and potentially reduce regulatory burdens, but also introduces integration risks. The resolution of the DOJ matter removes a significant overhang, but the company's long-term success depends on continued innovation and navigating a complex regulatory landscape.

What we're watching

Execution Risk
The company's ability to achieve the projected 35% adjusted EBITDA growth hinges on successfully accelerating SUBLOCADE dispense unit growth and realizing the benefits of the simplified operating model, which could be impacted by competitor actions or market dynamics.
Regulatory Headwinds
The opioid treatment market faces ongoing regulatory scrutiny and potential policy changes that could impact SUBLOCADE adoption and pricing, requiring Indivior to proactively manage these risks.
Governance Dynamics
The shift to a U.S. domicile and the creation of Indivior Pharmaceuticals, Inc. may introduce new governance complexities and require careful management of stakeholder expectations.

Related topics

Revenue Growth Pharmaceuticals